Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
ApexOnco Front Page
Recent articles
Arcus steps back from TIGIT as its Fc-silent claim crumbles.
Key FDA decisions are expected to face delays.
The Titan CD8-guiding technology seems to have spawned a new variant.
After trimming its cell therapy pipeline last year, the group is now out entirely.
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
A single-arm trial was enough for J&J’s Inlexzo nod.
